Biomarker for Hypophosphatasia Disease (BioHypophos) (NCT02603042) | Clinical Trial Compass
WithdrawnNot Applicable
Biomarker for Hypophosphatasia Disease (BioHypophos)
Stopped: Transition to BioMetabol
Germany, India, Sri Lanka0Started 2018-08-20
Plain-language summary
Development of a new MS-based biomarker for the early and sensitive diagnosis of Hypophosphatasia disease from plasma
Who can participate
Age range2 Months
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
IInclusion Criteria:
* Informed consent will be obtained from the patient or the parents before any study related procedures.
* Patients of both genders older than 2 month
* The patient has a diagnosis of Hypophosphatasia disease or a high-grade suspicion for Hypophosphatasia disease
* High-grade suspicion present, if one or more inclusion criteria are valid:
* Positive family anamnesis for Hypophosphatasia disease
* Frequent fractures
* Bone pain
* Tooth loss
* Osteopenia/Osteoporosis
* Craniosynostosis
Exclusion Criteria:
* No Informed consent from the patient or the parents before any study related procedures.
* Patients of both gender younger than 2 month
* No diagnosis of Hypophosphatasia disease or no valid criteria for profound suspicion of Hypophosphatasia disease
What they're measuring
1
Sequencing of the Hypophosphatasia disease related gene